Cambridge Healthtech Institute's Fifth Annual
( 抗体药物复合物 )
Engineering for Clinical Success
2018年1月9日 - 10日
Cambridge Healthtech Institute's Antibody-Drug Conjugates conference reveals the engineering that has brought about today's ADC revolution, and examines how to design safe and effective therapeutics. Exploring options for selecting new targets and ensuring potency will be discussed, along with strategies for advancing ADCs to the clinic. A special focus on fighting cancer will be highlighted including tumor penetration. Analyzing ADCs to explore conjugation, stability, and payloads will also be addressed in this leading ADC event.
Advancing ADCs into the Clinic
Pre-Clinical Development of a Novel FLT3 Targeting Antibody-Drug Conjugate Employing Site-Specific Conjugate for the Treatment of Acute Myeloid Leukemia
Kendall Morrison, Ph.D., Director, Protein Technologies, Agensys, Inc. (an affiliate of Astellas Pharma)
Analyzing ADCs to Improve Properties
Exploring Higher Order Structure of ADCs with Biophysical Characterization Techniques
David Chiu, Ph.D., Scientist, Analytical Sciences, Seattle Genetics
Understanding Stability of ADCs Utilizing Deconjugation of Small Molecule Drugs
Colin Medley, Ph.D., Senior Scientist, Small Molecule Pharmaceutical Sciences, Genentech, Inc.
Engineering Next-Gen ADCs
HydraSpace Technology: A Versatile Ionic Spacer to Further Empower Glycan-Conjugated Antibody-Drug Conjugates
Floris Van Delft, Ph.D., Founder & CSO, SynAffix BV
Improving Production of ADCs
The Impact of Trisulfide Modification of Antibodies on the Properties of Antibody-Drug Conjugates Manufactured Using Thiol Chemistry
Thomas Ryll, Ph.D., Vice President, Process and Analytical Development, ImmunoGen, Inc.
Strategy to Advance ARX788 ADC Program from Development to Clinical Manufacturing
Yun Bai, Ph.D., Director, Process Development, Ambrx, Inc.